Wockhardt Announces Successful Completion of Pivotal Phase 3 Pneumonia Study of its Macrolide Antibiotic Nafithromycin WCK 4873

Wockhardt Limited has successfully completed a pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873, which showed that an ultrashort course of three-day treatment with Nafithromycin is as effective as seven-day therapy with Moxifloxacin. The study also established that Nafithromycin has a remarkable feature of sustained high lung concentration and is effective against Gram-positive and fastidious Gram-negative pathogens, including Mycoplasma pneumoniae. The study did not encounter any serious adverse events, and all reported AEs were mild and unrelated to the study drugs.,